Summary & Overview
HCPCS C7554: Cystourethroscopy with Blue Light Fluorescent Imaging
HCPCS Level II code C7554 denotes cystourethroscopy performed with adjunctive blue light cystoscopy using a fluorescent imaging agent. This modality augments standard cystoscopic inspection by highlighting abnormal urothelial tissue under blue light after administration of a fluorescent agent, improving lesion visualization and potentially influencing diagnostic accuracy and intraoperative decision-making. Nationally, adoption of blue light cystoscopy has implications for urology practice patterns, capital and supply requirements, and payer coverage policies.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and service settings, a review of common billing and coding considerations, and summarized benchmarks where available. The publication also outlines typical sites of service, common modifiers associated with complex procedural coding, and areas where payers commonly document coverage criteria or prior authorization requirements.
This resource aims to help coding, billing, and clinical teams understand the scope of services represented by C7554, the clinical rationale for adjunctive blue light imaging in cystourethroscopy, and the types of documentation and procedural detail payers expect for claim adjudication. Data not available in the input are identified where applicable.
Billing Code Overview
HCPCS Level II code C7554 describes cystourethroscopy with adjunctive blue light cystoscopy using a fluorescent imaging agent. This procedure combines standard cystourethroscopy visualization with a blue light–activated fluorescent agent to enhance detection of bladder lesions.
-
Service type: Diagnostic/operative endoscopic urologic procedure with adjunctive fluorescent imaging
-
Typical site of service: Hospital outpatient department or ambulatory surgery center, where cystoscopic imaging and administration of a fluorescent agent can be performed safely and with required equipment
Clinical & Coding Specifications
Clinical Context
A typical patient is a 68-year-old male with a history of non-muscle invasive bladder cancer under surveillance after transurethral resection of bladder tumor (TURBT). He reports intermittent gross hematuria and prior atypical urine cytology. The urology team schedules an operative cystoscopy in an outpatient ambulatory surgery center or hospital outpatient department for diagnostic evaluation and potential therapeutic intervention. During the procedure the surgeon performs a cystourethroscopy with instillation of an intravesical fluorescent imaging agent and uses blue light (photodynamic) cystoscopy to enhance detection of carcinoma in situ and small papillary lesions. Findings may prompt targeted biopsies or repeat TURBT in the same session or at a subsequent visit. Typical site of service is the ambulatory surgery center or hospital outpatient department; general or monitored anesthesia care may be used depending on patient comorbidity and concurrent procedures. Common payors for prior authorization or claims review include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when procedural work is substantially greater than typical (document rationale and time). |